Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Impact of different surgical and postoperative adjuvant treatment modalities on survival of sinonasal malignant melanoma

Authors: Xin-Jun Meng, Hua-Fei Ao, Wei-Ting Huang, Fu Chen, Xi-Cai Sun, Jing-Jing Wang, Zhuo-Fu Liu, Wade W Han, Allison N Fry, De-Hui Wang

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

The role of postoperative adjuvant treatment for sinonasal malignant melanoma remains unclear. This study evaluates the impact of three different surgical and postoperative adjuvant treatment modalities: surgery alone(open and endoscopic approaches), surgery plus radiotherapy and surgery, radiotherapy plus chemotherapy on survival of patients with primary sinonasal malignant melanoma (SMM).

Methods

The data of 69 patients who underwent primary surgical treatments at Eye & ENT hospital of Fudan University between January 1st, 2000 and December 31st, 2010 were retrospectively reviewed. Survival comparison of different surgical and postoperative adjuvant treatment modalities (surgery alone, surgery plus radiotherapy and surgery, radiotherapy plus chemotherapy), as well as survival comparison between open and endoscopic surgical approaches were performed. Curves depicting survival were performed using Kaplan-Meier method. Statistical analysis was performed using log-rank test software SPSS19 and p < .05 is considered as statistically significant.

Results

The median overall survival time was found to be 18 months for surgery alone (27 cases), 32 months for surgery plus radiotherapy (24 cases), 42 months for surgery, radiotherapy plus chemotherapy (18 cases). The 3 and 5 year survival rates for groups mentioned above were 14.8% and 5.6%, 45.1% and 31.6%, 55% and 32.1%, respectively. Statistical significances were found not only between surgery alone and surgery plus radiotherapy treatment group (P = 0.012), but also surgery alone and surgery, radiotherapy plus chemotherapy group (P = 0.002). There was no statistically significant survival difference found between the two different surgical approaches (41 cases for open approach and 28 cases for endoscopic approach).

Conclusions

Sinonasal malignant melanoma is a disease with a poor prognosis. Patients who underwent surgery plus radiotherapy or surgery, radiotherapy plus chemotherapy had better survival outcomes than those underwent surgery alone. Endoscopic approach provided similar survival outcome as an open approach.
Appendix
Available only for authorised users
Literature
1.
Lund VJ, Stammberger H, Nicolai P, Castelnuovo P, Beal T, Beham A, Bernal-Sprekelsen M, Braun H, Cappabianca P, Carrau R, Cavallo L, Clarici G, Draf W, Esposito F, Fernandez-Miranda J, Fokkens W, Gardner P, Gellner V, Hellquist H, Hermann P, Hosemann W, Howard D, Jones N, Jorissen M, Kassam A, Kelly D, Kurschel-Lackner S, Leong S, McLaughlin N, Maroldi R, et al: European position paper on endoscopic management of tumours of the nose, paranasal sinuses and skull base. Rhinology. 2010, 2010 (Suppl 22): 1-143.
2.
Tas F, Keskin S: Mucosal melanoma in the head and neck region: different clinical features and same outcome to cutaneous melanoma. ISRN Dermatol. 2013, 2013: 5-Artical ID:586915CrossRef
3.
Sun CZ, Li QL, Hu ZD, Jiang YE, Song M, Yang AK: Treatment and prognosis in sinonasal mucosal melanoma: A retrospective analysis of 65 patients from a single cancer center. Head Neck. 2014, 36: 675-681. 10.1002/hed.23355.CrossRefPubMed
4.
Jangard M, Hansson J, Ragnarsson-Olding B: Primary sinonasal malignant melanoma: a nationwide study of the Swedish population, 1960–2000. Rhinology. 2013, 51: 22-30.PubMed
5.
Koivunen P, Back L, Pukkila M, Laranne J, Kinnunen I, Grenman R, Makitie AA: Accuracy of the current TNM classification in predicting survival in patients with sinonasal mucosal melanoma. Laryngoscope. 2012, 122: 1734-1738. 10.1002/lary.23343.CrossRefPubMed
6.
Gal TJ, Silver N, Huang B: Demographics and treatment trends in sinonasal mucosal melanoma. Laryngoscope. 2011, 121: 2026-2033.PubMed
7.
Owens JM, Roberts DB, Myers JN: The role of postoperative adjuvant radiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol. 2003, 129: 864-868. 10.1001/archotol.129.8.864.CrossRef
8.
Temam S, Mamelle G, Marandas P, Wibault P, Avril MF, Janot F, Julieron M, Schwaab G, Luboinski B: Postoperative radiotherapy for primary mucosal melanoma of the head and neck. Cancer. 2005, 103: 313-319. 10.1002/cncr.20775.CrossRefPubMed
9.
Gore MR, Zanation AM: Survival in Sinonasal Melanoma: A Meta-analysis. J Neuro Surg B. 2012, 73: 157-162.CrossRef
10.
Carolyn CC, Byrd DR, Garcia-Aguilar J, Kurtzman SH, Olawaiye A, Washington MK: AJCC cancer staging atlas : a companion to the seventh editions of the AJCC cancer staging manual and handbook. 2012, New York: Springer
11.
Suh JD, Ramakrishnan VR, Chi JJ, Palmer JN, Chiu AG: Outcomes and complications of endoscopic approaches for malignancies of the paranasal sinuses and anterior skull base. Ann Otol Rhinol Laryngol. 2013, 122: 54-59.CrossRefPubMed
12.
Arnold A, Ziglinas P, Ochs K, Alter N, Geretschlager A, Ladrach K, Zbaren P, Caversaccio M: Therapy options and long-term results of sinonasal malignancies. Oral Oncol. 2012, 48: 1031-1037. 10.1016/j.oraloncology.2012.04.005.CrossRefPubMed
13.
Prasad ML, Patel SG, Huvos AG, Shah JP, Busam KJ: Primary mucosal melanoma of the head and neck: a proposal for microstaging localized, Stage I (lymph node-negative) tumors. Cancer. 2004, 100: 1657-1664. 10.1002/cncr.20201.CrossRefPubMed
14.
Bachar G, Loh KS, O'Sullivan B, Goldstein D, Wood S, Brown D, Irish J: Mucosal melanomas of the head and neck: experience of the Princess Margaret Hospital. Head Neck. 2008, 30: 1325-1331. 10.1002/hed.20878.CrossRefPubMed
15.
Narasimhan K, Kucuk O, Lin HS, Heilbrun LK, Carron M, Venkatramanamoorthy R, Mathog R: Sinonasal mucosal melanoma: a 13-year experience at a single institution. Skull base. 2009, 19: 255-262. 10.1055/s-0028-1115321.CrossRefPubMedPubMedCentral
16.
Clifton N, Harrison L, Bradley PJ, Jones NS: Malignant melanoma of nasal cavity and paranasal sinuses: report of 24 patients and literature review. J Laryngol Otol. 2011, 125: 479-485. 10.1017/S0022215110002720.CrossRefPubMed
17.
Lund VJ, Chisholm EJ, Howard DJ, Wei WI: Sinonasal malignant melanoma: an analysis of 115 cases assessing outcomes of surgery, postoperative radiotherapy and endoscopic resection. Rhinology. 2012, 50: 203-210.PubMed
18.
Douglas CM, Malik T, Swindell R, Lorrigan P, Slevin NJ, Homer JJ: Mucosal melanoma of the head and neck: radiotherapy or surgery?. J Otolaryngol Head Neck Surg. 2010, 39: 385-392.PubMed
19.
Moreno MA, Roberts DB, Kupferman ME, DeMonte F, El-Naggar AK, Williams M, Rosenthal DS, Hanna EY: Mucosal melanoma of the nose and paranasal sinuses, a contemporary experience from the M, D Anderson Cancer Center. Cancer. 2010, 116: 2215-2223.PubMed
20.
Vandenhende C, Leroy X, Chevalier D, Mortuaire G: Sinonasal mucosal melanoma: retrospective survival study of 25 patients. J Laryngol Otol. 2012, 126: 147-151. 10.1017/S0022215111002519.CrossRefPubMed
21.
Enee V, Houliat T, Truilhe Y, Darrouzet V, Stoll D: [Malignant melanoma of the nasosinal mucosa. Retrospective study apropos of 20 cases]. Revue de laryngologie - otologie - rhinologie. 2000, 121: 243-250.PubMed
22.
Huang SF, Liao CT, Kan CR, Chen IH: Primary mucosal melanoma of the nasal cavity and paranasal sinuses: 12 years of experience. J Otolaryngol. 2007, 36: 124-129. 10.2310/7070.2007.0010.CrossRefPubMed
23.
Dauer EH, Lewis JE, Rohlinger AL, Weaver AL, Olsen KD: Sinonasal melanoma: a clinicopathologic review of 61 cases. Otolaryngol Head Neck Surg. 2008, 138: 347-352. 10.1016/j.otohns.2007.12.013.CrossRefPubMed
24.
Gavriel H, McArthur G, Sizeland A, Henderson M: Review: mucosal melanoma of the head and neck. Melanoma Res. 2011, 21: 257-266. 10.1097/CMR.0b013e3283470ffd.CrossRefPubMed
25.
Kanetaka S, Tsukuda M, Takahashi M, Komatsu M, Niho T, Horiuchi C, Matsuda H: Mucosal melanoma of the head and neck. Exp Therapeutic Med. 2011, 2: 907-910.
26.
Kingdom TT, Kaplan MJ: Mucosal melanoma of the nasal cavity and paranasal sinuses. Head Neck. 1995, 17: 184-189. 10.1002/hed.2880170303.CrossRefPubMed
27.
Lund VJ, Howard DJ, Harding L, Wei WI: Management options and survival in malignant melanoma of the sinonasal mucosa. Laryngoscope. 1999, 109: 208-211. 10.1097/00005537-199902000-00007.CrossRefPubMed
Metadata
Title
Impact of different surgical and postoperative adjuvant treatment modalities on survival of sinonasal malignant melanoma
Authors
Xin-Jun Meng
Hua-Fei Ao
Wei-Ting Huang
Fu Chen
Xi-Cai Sun
Jing-Jing Wang
Zhuo-Fu Liu
Wade W Han
Allison N Fry
De-Hui Wang
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-608

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Primary localized rectal/pararectal gastrointestinal stromal tumors: results of surgical and multimodal therapy from the French Sarcoma group

Research article

A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

Research article

A panel of tumor markers, calreticulin, annexin A2, and annexin A3 in upper tract urothelial carcinoma identified by proteomic and immunological analysis

Research article

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer

Research article

A new technique combining virtual simulation and methylene blue staining for the localization of small peripheral pulmonary lesions

Research article

Helical intensity-modulated Radiotherapy of the Pelvic Lymph Nodes with Integrated Boost to the Prostate Bed - Initial Results of the PLATIN 3 Trial
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits